AJP - Regu Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 291: R684-R691, 2006. First published April 13, 2006; doi:10.1152/ajpregu.00873.2005
0363-6119/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
291/3/R684    most recent
00873.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munger, K. A.
Right arrow Articles by Lortie, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munger, K. A.
Right arrow Articles by Lortie, M. J.

INFLAMMATION AND CYTOKINES

Acute renal response to LPS: impaired arginine production and inducible nitric oxide synthase activity

Karen A. Munger,1 Roland C. Blantz,2,3,4 and Mark J. Lortie2,3,4

1Department of Internal Medicine, Avera Research Institute, University of South Dakota School of Medicine, Sioux Falls, South Dakota; and 2Division of Nephrology and Hypertension, University of California San Diego School of Medicine, San Diego; 3Veterans Medical Research Foundation, San Diego; and 4Veterans Administration Healthcare System, San Diego, California

Submitted 13 December 2005 ; accepted in final form 7 March 2006

We have previously shown in rats that lipopolysaccharide (LPS) causes both decreased renal perfusion and kidney arginine production before nitric oxide (NO) synthesis, resulting in a >30% reduction in plasma arginine. To clarify the early phase effects of LPS, we asked the following two questions: 1) is the rapid change in renal arginine production after LPS simply the result of decreased substrate (i.e., citrulline) delivery to the kidney or due to impaired uptake and conversion and 2) is the systemic production of NO limited by plasma arginine availability after LPS? Arterial and renal vein plasma was sampled at 30-min intervals from anesthetized rats with or without citrulline or arginine (2 µmol·min–1·kg–1 iv) a dose with no effect on MAP, renal function, or NO production. Exogenous citrulline was quickly converted to arginine by the kidney, resulting in plasma levels similar to equimolar arginine infusion. Also, the increase in citrulline uptake resulted primarily from increased filtered load and reabsorption. In a separate series, citrulline was infused after LPS administration, verifying that citrulline uptake and conversion persists during impaired kidney function. Last, in rats given LPS, the elevation of plasma arginine had no discernable impact on mean arterial pressure, kidney function, or systemic NO production. This work demonstrates how arginine synthesis is normally "substrate limited" and explains how impaired kidney perfusion quickly results in decreased plasma arginine. However, contrary to in vitro studies, the significant reduction in extracellular arginine during the early phase response to LPS in vivo is not functionally rate limiting for NO production.

citrulline; arginase; argininosuccinate; high-performance liquid chromatography



Address for reprint requests and other correspondence: M. J. Lortie, Division of Nephrology and Hypertension (151) VASDHS, 3350 La Jolla Village Dr., San Diego, CA 92161 (e-mail: mlortie{at}ucsd.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.